Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article info

PostScript

Letter

Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

Authors

Mohamed Attauabi Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Copenhagen, Denmark Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, Denmark PubMed articles Google scholar articles
Jakob Seidelin Department of Gastroenterology and Hepatology, Herlev Hospital, University of Copenhagen, Herlev, Denmark PubMed articles Google scholar articles
Johan Burisch Gastrounit, Medical Division, Copenhagen University Hospital, Hvidovre, Hvidovre, Denmark Copenhagen Center for Inflammatory Bowel Disease in Children, Adolescents and Adults, University of Copenhagen, Hvidovre Hospital, Copenhagen, Denmark PubMed articles Google scholar articles
Danish COVID-IBD Study Group
Google scholar articles

Correspondence to Dr Mohamed Attauabi, Gastrounit, Medical Division, Hvidovre Hospital, 2650 Hvidovre, Denmark; attauabi12{at}gmail.com

Citation

Attauabi M, Seidelin J, Burisch J Danish COVID-IBD Study Group

Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?

Gut 2021;70:2020-2022.

Publication history

Received February 12, 2021
Revised February 19, 2021
Accepted February 24, 2021
First published March 3, 2021.

Online issue publication

September 08, 2021

Article Versions

Previous version (3 March 2021).
You are viewing the most recent version of this article.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage